Cynata Therapeutics Limited
CYYNFOTCHealthcare● Active
$0.15
$-0.07(-32.58%)
Market Cap$36518100
P/E Ratio—
52W High$0.2225
52W Low$0.08
Cynata Therapeutics Limited (CYYNF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYYNF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.89M | $2.32M | $1.65M | $7.77M | $1.55M |
| Cost of Revenue | $0.00M | $0.28M | $0.28M | $0.28M | $0.28M |
| Gross Profit | $1.89M | $2.03M | $1.37M | $7.49M | $1.27M |
| Gross Margin %(computed) | 100.00% | 87.88% | 83.08% | 96.40% | 81.89% |
| Operating Expenses | |||||
| R&D Expenses | $7.68M | $8.96M | $12.67M | $9.10M | $4.06M |
| G&A Expenses | $0.00M | $0.00M | $3.18M | $3.99M | $4.22M |
| Total Operating Expenses | $10.01M | $11.12M | $16.26M | $12.06M | $7.35M |
| Operating Income | ($8.12M) | ($8.81M) | ($13.00M) | ($4.29M) | ($5.81M) |
| Operating Margin %(computed) | -430.95% | -380.37% | -785.80% | -55.17% | -375.61% |
| Interest Income | $0.23M | $0.42M | $0.35M | $0.06M | $0.09M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($9.39M) | ($12.06M) | ($14.28M) | ($5.45M) | ($7.69M) |
| Income Tax Expense | $0.00M | ($2.32M) | $0.00M | $0.00M | $0.00M |
| Net Income | ($9.39M) | ($9.74M) | ($14.28M) | ($5.45M) | ($7.69M) |
| Net Margin %(computed) | -498.14% | -420.82% | -863.05% | -70.08% | -497.38% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.05 | $-0.05 | $-0.10 | $-0.04 | $-0.06 |
| Wtd Avg Shares | 204.95M | 179.63M | 145.09M | 143.28M | 130.43M |
| EBITDA | ($9.33M) | ($9.95M) | ($16.26M) | ($13.56M) | ($8.80M) |
| EBITDA Margin %(computed) | -494.81% | -429.70% | -983.04% | -174.48% | -569.22% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Cynata Therapeutics Limited data
About Cynata Therapeutics Limited (CYYNF) Income Statement
Cynata Therapeutics Limited (CYYNF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CYYNF reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.01B) — a net profit margin of -498.14%.
Frequently asked questions
CYYNF · 4 questionsCynata Therapeutics Limited (CYYNF) reported revenue of $0.00B for 2025, down 18.6% year-over-year.
CYYNF revenueCYYNF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09